NCT03972527View on ClinicalTrials.gov

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

June 26, 2024

Study Completion Date

July 18, 2024

Conditions
Oral Mucositis (Ulcerative)Oral Mucositis (Ulcerative) Due to RadiationOral Mucositis (Ulcerative) Due to Antineoplastic TherapyHead and Neck Cancer
Interventions
DEVICE

Photobiomodulation

Provide photobiomodulation therapy to subjects prior to each radiation therapy session.

OTHER

Routine Oral Care and Analgesia

Standard oral care, oral hygiene and oral pain protocols

Trial Locations (12)

10016

NYU Langone, New York

14215

Erie County Medical Center, Buffalo

29216

University of Mississippi Medical Center, Jackson

33176

Miami Cancer Institute, Miami

35294

University of Alabama at Birmingham, Birmingham

41017

St. Elizabeth Healthcare, Edgewood

43210

James Cancer Hospital at The Ohio State University, Columbus

44109

MetroHealth, Cleveland

45219

The Christ Hospital, Cincinnati

71103

Willis-Knighton Cancer Center, Shreveport

74146

Oklahoma Cancer Specialtists and Research Intstitute, Tulsa

90805

The Oncology Institute, Long Beach

All Listed Sponsors
lead

MuReva Phototherapy Inc.

INDUSTRY